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ABSTRACT
Mitochondria are dynamic organelles frequently undergoing fission and fusion 
events to maintain their integrity, bioenergetics and spatial distribution, which is 
fundamental to the processes of cell survival. Disruption in mitochondrial dynamics 
plays a role in cancer. Therefore, proteins involved in regulating mitochondrial 
dynamics are potential targets for treatment. mDIVI1 is an inhibitor of the 
mitochondrial fission protein DRP1, which induces i) mitochondrial oxidative stress 
and ii) effectively reduces mitochondrial metabolism. We show here that mDIVI1 is 
able to inhibit 3D tumorsphere forming capacity, cell migration and stemness-related 
signalling in breast cancer cells, indicating that mDIVI1 can potentially be used for 
the therapeutic elimination of cancer stem cells (CSCs).
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INTRODUCTION
Mitochondria are extremely dynamic organelles in 
constant division, elongation and connection to each other 
to form tubular networks or fragmented granules in order 
to satisfy the requirements of the cell and adapt to the 
cellular microenvironment. The balance of mitochondrial 
fusion and fission dictates the morphology, abundance, 
function and spatial distribution of mitochondria, therefore 
influencing a plethora of mitochondrial-dependent 
vital biological processes such as ATP production, 
mitophagy, apoptosis and calcium homeostasis [1]. 
In turn, mitochondrial dynamics can be regulated by 
mitochondrial metabolism, respiration and oxidative 
stress [2]. Thus, it is not surprising that an imbalance 
of fission and fusion activities has a negative impact on 
several pathological conditions, including cancer. Cancer 
cells often exhibit fragmented mitochondria, and enhanced 
fission or reduced fusion is often associated with cancer, 
although a comprehensive mechanistic understanding on 
how mitochondrial dynamics affects tumorigenesis is still 
needed [3].
A master regulator of the mitochondrial fission 
machinery is the cytoplasmic dynamin-related protein 1 
(DRP1, also known as DNM1L). During mitochondrial 
fission DRP1 is recruited to the mitochondria, where 
it interacts with its outer mitochondrial membrane 
receptors. Subsequently, DRP1 polimerizes and promotes 
mitochondrial constriction and fission, activities that are 
fuelled by its GTPase activity [4]. 
The discovery of a derivative of quinazolinone, the 
mitochondrial DIVision Inhibitor 1 (mDIVI1), a small 
molecule that selectively and reversibly inhibits DRP1 
[5] (Figure 1A), has helped to shed new light on the role 
of mitochondrial dynamics in cancer. mDIVI1 has been 
shown to target DRP1 by binding and suppressing both the 
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DRP1 self-assembly into ring-like structures around the 
mitochondria and its capacity to catalyze GTP hydrolysis. 
mDIVI1 prompts a rapid formation of interconnected 
mitochondria without overtly affecting other cellular 
structures such as the cytoskeleton or the endoplasmic 
reticulum. The IC50 of mDIVI1 ranges from 1 to 50 
µM depending on the cell type [5]. In contrast to the 
cytoprotective effect in neurons and cardiovascular cells, 
mDIVI1 has a cytotoxic effect in hyperproliferative cancer 
cells and immortalised cell lines [4]. Indeed, high DRP1 
expression or activation has been described in several 
malignancies, and it promotes mitochondrial fission 
in cancer cells, which plays an important role in their 
proliferation and metastatic capacity [4]. Reversal of that 
mitochondrial fission via DRP1 inhibition with mDIVI1 
induces apoptosis via cytochrome c release and cell cycle 
arrest by impairing the assembly of mitotic spindles and 
cytokinesis, consequently leading to aneuploidy [3, 4].  
Finally, emerging evidence points toward a role 
for mitochondrial fusion and fission, and in particular 
for DRP1, in regulating the proliferation and survival 
of cancer stem cells (CSC), which are thought to 
be responsible for treatment failure and metastatic 
dissemination. DRP1-dependent fission confers 
chemoresistance, as chemoresistant cancer cells are 
prone to form highly interconnected mitochondrial 
networks. mDIVI1 treatment reverses this phenotype by 
re-sensitising chemoresistant cancer cells [6]. Moreover, 
high DRP1 expression and mitochondrial fragmentation 
contribute to maintenance of brain tumour-initiating cells, 
and genetic ablation of DRP1 or its pharmacological 
inhibition with mDIVI1 reduces their tumorigenicity in 
vitro and in vivo [7]. Of note, DRP1-dependent fission 
has been found to be essential for stem cell maintenance 
in immortalised mammary epithelial stem-like cells. 
Upon asymmetric cell division, stem-like cells contained 
a higher abundance of newly generated mitochondria, 
whereas cells with more aged mitochondria were growing 
less efficiently in anchorage-independent conditions 
and were primed to differentiate. DRP1 inhibition 
with mDIVI1 abolished the mitochondrial asymmetric 
distribution of mitochondria reducing stem-cell properties 
in vitro, suggesting that mitochondrial fitness regulates 
stemness [8]. Finally, inactivation of DRP1 with mDIVI1 
seems to impede pluripotency reprogramming [9, 10]. 
Specific eradication of CSCs represents one of the most 
challenging goals of current cancer research, as it could 
potentially achieve a permanent cure for cancer patients. 
Emerging evidence has recently shown that CSCs 
are critically dependant on mitochondrial function for 
their successful propagation and survival [11–13]. In the 
current study, we hypothesised that the pharmacological 
inhibition of DRP1-induced mitochondrial fission with 
mDIVI1 would target breast CSC survival via induction of 
mitochondrial dysfunction and repression of mitochondrial 
metabolism, extending our previous studies. We show 
that exposure of MCF7 breast cancer cells to mDIVI1 
transforms these cells in metabolically less active cells, 
with minor ATP demand, possibly via induction of 
mitochondrial reactive species. These mDIVI1-treated 
metabolically-repressed MCF7 cells show reduced 
tumorsphere forming capacity, decreased migration and 
inhibited stemness-related signalling. mDIVI1 is also 
able to decrease tumorsphere formation efficiency in 
melanoma and lung cancer cell lines, strongly suggesting 
that mDIVI1 treatment decreases the abundance of CSC 
also in these cancers, hence pointing it out as a new anti-
CSC drug for cancer therapy. 
RESULTS
In this study we aimed to assess the effects of 
mDIVI1, an inhibitor of the mitochondrial division protein 
DRP1, on mitochondrial function and CSC behaviour. 
MDIVI1 treatment reduces MCF7 cell viability
First of all, we sought to evaluate whether mDIVI1-
induced inhibition of DRP1 would have a repercussion 
on the viability of MCF7 cells. Exposure to mDIVI1 
for 48 hours did not decrease viability of MCF7 cells at 
a concentration of 10 µM, and significantly reduced it 
by 20% at 50 µM and 100 µM, as measured using the 
PrestoBlue assay, a resazurin-based viability assay (Figure 
1B). Similar results were obtained using the Bradford 
assay, which measures protein content, as an indicator 
of cell viability (Figure 1C). Only exposure to higher 
concentrations of mDIVI1 (20 and 50 µM) significantly 
reduced MCF7 protein content after 2 days of treatment. 
Five days of treatment did have a bigger impact on MCF7 
cell viability, significantly diminishing it by 20% at a 
concentration of 10 µM, by over 65% at 50 µM and 85% 
at 100 µM (Figure 1B). 
Thus, mDIVI1 reduces the viability of MCF7 
cells mostly at higher concentrations and after 5 days of 
treatment. 
MDIVI1 increases MCF7 mitochondrial mass 
and mitochondrial oxidative stress 
In order to assess whether the inhibition of 
DRP1 was actually being translated into a reduction in 
mitochondrial fission, we aimed to stain the mitochondria 
of MCF7 cells with Mitotracker Deep Red, which is 
a marker of mitochondrial mass. mDIVI1 treatment 
led to more interconnected mitochondria, with slightly 
increased mitochondrial calibres, which could be a result 
of the absence of fission activity (Supplementary Figure 1). 
Mitochondrial mass was also quantified by flow cytometry. 
Mitotracker Deep Red mean fluorescence intensity was 
found to be significantly higher after 5 days of treatment with 
50 µM mDIVI1, indicating that at higher concentrations, 
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mDIVI1-mediated DRP1 inhibition is able to increase the 
mitochondrial mass of MCF7 cells (Figure 2A).
We hypothesised that an inhibition of the 
mitochondrial fission would have an impact on other 
mitochondrial processes such as mitochondrial metabolism 
and general and mitochondrial oxidative stress. To test 
that, MCF7 cells were stained with MitoSOX and CM-
H2DCFDA, and mitochondrial superoxide and total ROS 
were quantified by flow cytometry. MitoSOX staining 
quantification in MCF7 cells revealed that exposure to 
both concentrations of mDIVI1 significantly increased 
mitochondrial superoxide production compared to vehicle-
treated cells (Figure 2B). However, general oxidative 
stress levels did not change after exposure to mDIVI1. 
Figure 1. DRP1 inhibition by mDIVI1 reduces MCF7 cell viability. (A) mDIVI1 chemical structure (B) The mitochondrial fission 
inhibitor mDIVI1 did not decrease viability of MCF7 cells at a concentration of 10 µM, and significantly reduced it at 50 µM and 100 µM at 
48 hours. Five days of treatment induced a bigger reduction of MCF7 viability (N = 3). (C) mDIVI1 slightly decreased protein content of MCF7 
cells at a concentration of 10 µM and reduced it by almost 40% at 50 µM after 48 hours of treatment as measured using the Bradford assay 
(N = 6). Data represented as MEAN ± SEM. One sample t test, *p value < 0.05, **p value  <  0.01 and ***p value < 0.001. 
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Only 5 days of treatment showed a slight trend toward 
an increase in the production of total ROS (Figure 2C). 
Of note, whereas the increase in general ROS goes in 
line with the increase in mitochondrial content, the boost 
in the levels of mitochondrial superoxide in mDIV1-
treated cells is actually bigger than the observed increased 
mitochondrial content. 
Thus, mDIVI1 treatment slightly increase 
mitochondrial mass and clearly induced the generation 
of mitochondrial superoxide without any major effects on 
MCF7 general oxidative stress.
MDIVI1 reduces glycolytic capacity, respiration 
and ATP production of MCF7 cells
We hypothesised that inhibition of mitochondrial 
fission would be enough to block the normal functioning 
of mitochondrial metabolism. Indeed, it has been shown 
that a DRP1 mutant that inhibits mitochondrial fission 
increases glucose uptake and lactate production, and 
decreases ATP production [14]. Thus, we next aimed to 
measure the glycolytical function and the mitochondrial 
respiration in MCF7 cells exposed to mDIVI1. The 
extracellular acidification rate (ECAR) and the oxygen 
consumption rate (OCR) were measured using an XF96 
Extracellular Flux Analyser (Figures 3A and 4A). Basal 
glycolysis, glycolytic capacity and glycolytic reserve 
were calculated after addition of glucose, oligomycin 
and 2-deoxyglucose (2DG) into the media. Surprisingly, 
exposure to mDIVI1 did not have a significant effect 
on basal glycolysis. However, the glycolytic capacity 
and glycolytic reserve of MCF7 cells was reduced after 
treatment with mDIVI1 (Figure 3B). That is, treatment 
with mDIVI1 for 48 hours blocked the increase of 
the ECAR usually linked to the oligomycin-induced 
inhibition of mitochondrial complex V of the electron 
transport chain, indicating that mDIVI1-treated MCF7 
either have less ATP demand or have a less efficient 
mitochondrial oxidative phosphorylation than vehicle-
treated cells. Thus, to measure basal respiration, ATP 
production, maximal respiration and spare respiratory 
capacity, oxygen consumption was also calculated after 
addition of oligomycin, FCCP and antimycin/rotenone 
into glucose-containing media. In fact, exposure to 
mDIVI1 for 48 hours significantly reduced the oxygen 
consumption linked to basal respiration, ATP production 
and to a lesser extent, maximal respiration at higher 
concentrations (Figure 4B). However, it slightly increased 
the spare respiratory capacity of MCF7 cells after 
treatment with all mDIVI1 concentrations, suggesting 
that basal respiration in mDIVI1-treated is further from its 
theoretical maximum than vehicle-treated cells. The OCR 
versus ECAR graph was also plotted to have an indication 
of the metabolic state of the cell. mDIVI1 treatment also 
decreased dose-dependently the OCR/ECAR ratio of 
MCF7 cells compared to vehicle, indicating that mDIVI1-
treated MCF7 cells are less aerobic and metabolically 
less active (Figure 4C). Thus, mDIVI1-induced inhibition 
of mitochondrial fission functionally targets oxidative 
phosphorylation and also the glycolytic function of 
MCF7 cells, transforming them into cells with lower 
mitochondrial energetic needs.
To identify differentially regulated proteins upon 
treatment with mDIVI1, MCF7 cells were exposed for 
48 hours to either vehicle or 10 µM mDIVI1 and cell 
lysates were subject to label-free quantitative proteomics. 
Following protein digestion with trypsin, peptide fractions 
were processed on an LTQ-Orbitrap XL mass spectrometer. 
Those peptides identified were further analysed to find 
proteomic changes between mDIVI1-treated and vehicle-
treated MCF7 cells, as described before [15]. To define 
differential regulation, those identified proteins that 
showed a fold change difference of 1.5 or higher, and 
p values of  < 0.05 (ANOVA) compared to vehicle were 
considered. First, we searched the proteomics datasets for 
changes in proteins involved in metabolism (summarised in 
Table 1). The expression of several glycolytic enzymes, as 
well as pentose phosphate pathway enzymes and enzymes 
involved in mitochondrial metabolism were found to be 
down-regulated in mDIVI1-treated MCF7 cells compared 
to vehicle treatment. Of note, hexokinase, which generates 
glucose 6-phosphate from glucose for the glycolytic and 
the pentose phosphate pathways, was infinitely down-
regulated. In fact, the first two enzymes of the oxidative 
branch of the pentose phosphate pathway were also found 
downregulated in mDIVI1-treated cells compared to 
vehicle-treated cells (Table 1). That may possibly translate 
into a loss of antioxidant power, as the pentose phosphate 
pathway is a major source of NADPH. Furthermore, 
components of the complex III and V of the electron 
transport chain were found to be highly downregulated in 
mDIVI1-treated MCF7 cells (Table 1). To obtain additional 
functional insights into pathways that are differentially 
regulated in mDIVI1-treated MCF7 cells, bioinformatics 
analysis of the proteomics datasets were conducted.  All 
proteins were analysed using the Ingenuity Pathway 
Analysis software (IPA) to seek altered canonical pathways 
and toxicity functions. Of note, amongst the altered 
pathways identified by IPA in the mDIVI1-treated cells 
were pathways involved in metabolism such as pentose 
phosphate pathway, mTOR signalling, AMPK and protein 
kinase A signalling, fatty acid biosynthesis, cholesterol and 
palmitate biosynthesis, mevalonate pathway and ketolysis. 
Likewise, the toxicity functions found to be altered in 
mDIVI1-treated MCF7 cells compared with vehicle 
treatment included decreases in permeability transition 
of mitochondria and mitochondrial membrane, fatty acid 
metabolism and cholesterol biosynthesis (Table 2). Thus, 
besides mitochondrial respiration and glycolysis, fatty 
acid metabolism also seems to be altered in mDIVI1-
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Figure 2: Treatment of MCF7 cells with mDIVI1 significantly increases their mitochondrial mass and mitochondrial 
oxidative stress at 50 µM. (A) Mitotracker Deep Red mean intensity significantly increased after 5 days of treatment with 50 µM of 
mDIVI1. (B) Mitochondrial superoxide production significantly increased after 24 hour, 2 and 5 days of treatment. (C) Total ROS levels 
were not altered after exposure to mDIVI1. Data represented as MEAN ± SEM. One sample t test, *p value < 0.05, **p value < 0.01 and 
***p value < 0.001. N = 3.
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Figure 3: mDIVI1 treatment significantly reduces the glycolytic capacity of MCF7 cells without having an effect on 
basal glycolysis, hence decreasing their glycolytic reserve. (A) Extracellular acidification rate (ECAR) of MCF7 cells treated with 
either vehicle or mDIVI1 for 48 hours and assessed using the Seahorse XFe96 Analyzer. (B) Treatment with ≥10 µM mDIVI1 for 48 hours 
blocks the increase of ECAR usually linked to oligomycin inhibition of the mitochondrial respiration, indicating a significant reduction 
in glycolytic capacity and reserve. mDIVI1-treated cells are using glycolysis closer to its maximum capacity compared to vehicle-treated 
cells. Data represented as MEAN ± SEM. One way ANOVA, Dunnett’s multiple comparisons test, *p value < 0.05, **p value < 0.01 and 
***p value < 0.001. N ≥ 3. 
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Figure 4: mDIVI1 treatment significantly reduces the respiration and ATP production of MCF7 cells but increases 
their spare respiratory capacity. (A) Oxygen consumption rate (OCR) of MCF7 cells treated with either vehicle or mDIVI1 for 48 
hours and assessed using the Seahorse XFe96 Analyzer. (B) Treatment with mDIVI1 for 48 hours decreases the oxygen consumption 
linked to basal respiration, ATP production and to a lesser extent, maximal respiration. However it increases the spare respiratory capacity 
of MCF7cells, suggesting that mDIVI1-treated cells may be able to manage better an energetic crisis. (C) mDIVI1 treatment decreases 
the OCR/ECAR ratio of MCF7 cells indicating that mDIVI1-treated MCF7 cells are less aerobic and less metabolically active. Data 
represented as MEAN ± SEM. One way ANOVA, Dunnett’s multiple comparisons test, *p value < 0.05, **p value < 0.01 and ***p value < 
0.001. N = 3. 
Oncotarget13261www.impactjournals.com/oncotarget
Table 1: Changes in the expression of enzymes involved in several cellular metabolic pathways after exposure of MCF7 
cells to mDIVI1 for 48 hours as measured by label-free quantitative proteomics
Glycolysis 10 µM mDIVI1
 Hexokinase 1 HK1 ↓Infinite
 Fructose-bisphosphate aldolase A ALDOA ↓ 2.88
 Enolase 1 ENO1 ↓ 6.63
Post-Glycolysis Processes
 Pyruvate dehydrogenase PDHB ↑ 1.63
Pentose Phosphate Pathway
 6-phosphogluconolactonase PGLS ↓ 1.56
 Phosphogluconate dehydrogenase PGD ↓ 3.91
 Transketolase 
TCA Cycle TKT ↑ 2.06
 Citrate synthase, mitochondrial CS ↓ 1.51
 Isocitrate dehydrogenase
IDH2 ↑ 1.84
IDH3G ↓ 1.51
Oxidative Phosphorylation
 NADH dehydrogenase (complex I) MT-ND5
NDUFV1 ↓ 1.63
↑ 1.84
Coenzyme Q – cytochrome c reductase (complex III) UQCRC1 ↓ 2569.35
 Cytochrome c  oxidase (complex IV) COX6A1 ↑ 1.70
 ATP synthase (complex V) ATP5O ↓ 13.56
Fatty Acid Oxidation
 Acetyl-Coenzyme A acyltransferase 1, peroxisomal ACAA1 ↑ 3.96
 Acetyl-Coenzyme A acyltransferase 2, mitocondrial ACAA2 ↓ 2.09
 Long-chain-aldehyde dehydrogenase ALDH3A2 ↑ 4.40
 Delta-1-pyrroline-5-carboxylate dehydrogenase, mitochondrial ALDH4A1 ↑ 2.40
 4-trimethylaminobutyraldehyde dehydrogenase ALDH9A1 ↑ 1.72
 Acyl-CoA dehydrogenase family member 9, mitochondrial ACAD9 ↓ 1.94
 Carnitine O-palmitoyltransferase 2, mitochondrial CPT2 ↑ 3.15
Fatty Acid Synthesis
 Fatty acid synthase FASN ↑ 1.97
 Beta-ketoacyl-ACP synthase OXSM ↓ 1.61
Ketolysis/Ketogenesis
 Acetyl-CoA acetyltransferase, mitochondrial ACAT1 ↓ 2.40
 3-oxoacid CoA-transferase 1, mitochondrial OXCT1 ↑ 1.64
 3-hydroxy-3-methylglutaryl-CoA synthase 1 HMGCS1 ↑ 4.09
Lipid Metabolism (Other)
 short/branched chain specific acyl-CoA dehydrogenase ACADSB ↓ 2.92
 Cytochrome P450 1B1 CYP1B1 ↑ 19.96
 Cytochrome P450, family 1, subfamily A, polypeptide 1 CYP1A1 ↑ 190.30
 Lanosterol 14 α-demethylase CYP51A1 ↑ 3.41
 Lanosterol synthase LSS ↓ 1.82
 Farnesyl-diphosphate farnesyltransferase 1 FDFT1 ↓ 1.50
 Isopentenyl-diphosphate delta isomerase IDI1 ↓ 1.79
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Table 2: Pathway analysis of differentially expressed proteins in MCF7 cells treated with mDIVI1 compared to vehicle-
treated cells
Ingenuity canonical pathways -log (p-value) Z score Ratio
Remodeling of Epithelial Adherens Junctions 13.6 −0.30 0.348
Actin Cytoskeleton Signaling 11.5 −1.15 0.176
Germ Cell-Sertoli Cell Junction Signaling 9.79 0.183
EIF2 Signaling 9.4 −0.83 0.173
Epithelial Adherens Junction Signaling 8.9 0.189
Tight Junction Signaling 8.68 0.175
Integrin Signaling 8.46 −0.36 0.156
ILK Signaling 8.38 0.73 0.161
Regulation of eIF4 and p70S6K Signaling 8.17 −1.41 0.175
Paxillin Signaling 7.85 −0.69 0.2
Caveolar-mediated Endocytosis Signaling 7.42 0.239
Sertoli Cell-Sertoli Cell Junction Signaling 7.07 0.156
Regulation of Actin-based Motility by Rho 6.77 −0.73 0.207
Phagosome maturation 6.61 0.178
Clathrin-mediated Endocytosis Signaling 6.48 0.143
Regulation of Cellular Mechanics by Calpain Protease 5.75 −2.24 0.236
RhoA Signaling 5.26 −0.94 0.158
Mitotic Roles of Polo-Like Kinase 5.05 0.82 0.206
RhoGDI Signaling 4.95 0.85 0.134
Protein Ubiquitination Pathway 4.71 0.114
Role of BRCA1 in DNA Damage Response 4.66 0.179
Leukocyte Extravasation Signaling 4.62 −0.63 0.122
mTOR Signaling 4.53 0.63 0.123
Actin Nucleation by ARP-WASP Complex 4.15 −1.51 0.196
FAK Signaling 4.1 0.153
DNA Double-Strand Break Repair by Non-Homologous End Joining 3.42 0.357
Signaling by Rho Family GTPases 3.35 −0.41 0.102
Estrogen Receptor Signaling 3.29 0.125
Superpathway of Cholesterol Biosynthesis 2.79 0.222
Cleavage and Polyadenylation of Pre-mRNA 2.69 0.333
AMPK Signaling 2.66 −0.63 0.101
Palmitate Biosynthesis I 2.62 1
Fatty Acid Biosynthesis Initiation II 2.62 1
Calcium Signaling 2.39 −0.81 0.1
Cdc42 Signaling 2.37 −0.83 0.109
Rac Signaling 2.36 −0.83 0.112
Telomere Extension by Telomerase 2.3 0.267
RAN Signaling 2.19 0.25
Assembly of RNA Polymerase I Complex 2.11 0.333
ERK/MAPK Signaling 2.07 −0.47 0.0909
Cell Cycle Control of Chromosomal Replication 2.04 0.185
PAK Signaling 2.02 −0.30 0.11
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treated MCF7 cells, as observed by label-free quantitative 
proteomics. 
MDIVI1 reduces tumorsphere formation in 
MCF7 breast cancer, A375 melanoma and A549 
lung cancer cell lines
As mDIVI1 functioned as an inhibitor of 
mitochondrial oxidative phosphorylation in MCF7 
breast cancer cells, we next examined the effects of this 
mitochondrial fission inhibitor on the behaviour of CSCs, 
as it has been previously described that CSCs depend 
on mitochondrial metabolism for their survival and 
propagation [11–13]. 
One of the gold standard techniques for the study 
and identification of CSCs is the sphere formation assay, 
an in vitro culture system that enriches for CSCs. Under 
these anchorage-independent culture conditions, CSCs 
preferentially form the so-called tumorspheres, whereas 
more differentiated cells die rapidly. Hence, MCF7 cells 
were grown in suspension as tumorspheres and treated 
with either vehicle or mDIVI1 at increasing concentrations. 
Five days of exposure to mDIVI1 decreased MCF7 breast 
tumorsphere number by 50% at a concentration of 10 µM 
by 80% at 50 µM and 95% at 100 µM compared to vehicle 
treated cells (Figure 5A). Likewise, A375 melanoma and 
A549 lung tumorsphere forming capacity were significantly 
diminished after treatment with mDIVI1, again in a dose-
dependent fashion (by over 35% and 15% at a concentration 
of 10 µM and by over 90% and 80% at 50 µM, respectively) 
(Figure 5B and 5C). Inhibition of DRP1 with mDIVI1 
seemed to not only decrease tumorsphere number but also 
tumorsphere size (Figure 5C). Thus, mDIVI1 inhibited 
tumorsphere formation in a dose-dependent manner 
not only in the breast cancer cell line MCF7, but also in 
melanoma (A375) and lung cancer (A549) cell lines.
MDIVI1 inhibits migration of MCF7 cells 
It is though that CSCs are responsible for metastatic 
spread and growth. Emerging evidence highlights the role 
of mitochondrial dynamics in tumour cell dissemination 
[3]. These studies suggest that mitochondria are transferred 
to sites with high-energy demand. In migrating cancer 
cells mitochondria accumulate at the leading edge where 
processes requiring high energy occur, such as formation 
of focal adhesions. Fission seems to be a prerequisite 
for that efficient relocation of mitochondria. Indeed, 
upregulation/activation of DRP1 is associated with a 
migratory and invasive phenotype in cancer [3]. Thus, we 
next sought to assess whether mDIVI1-induced inhibition 
of DRP1 would decrease the migration of MCF7. To that 
purpose we performed a scratch assay, were cells were 
cultured in the presence of either vehicle or mDIVI1. The 
scratch was monitored over time and the percentage of 
wound closure was measured as described previously [16]. 
Exposure to 10 and 50 µM mDIVI1 significantly reduced 
the percentage of wound closure compared to vehicle-
treated cells on a 14% and 44% respectively, therefore 
indicating a clear mDIVI1-induced dose-dependent 
reduction in MCF7 cell migration (Figure 6). 
In addition, amongst the altered pathways identified 
by IPA in the mDIVI1-treated cells, there were pathways 
involved in cell motility such as actin cytoskeleton 
signalling, regulation of actin-based motility by rho, 
regulation of cellular mechanics by calpain protease 
(clearly predicted to be inactivated), cdc42 or RhoA 
signalling, and PAK signalling (Table 2). Likewise, some 
of the biological functions identified by IPA as affected 
by mDIVI1 involved cellular movement, migration 
and invasion, which in most cases was predicted to be 
decreased (Table 3).
Protein Kinase A Signaling 2.01 −1.61 0.0775
Apoptosis Signaling 1.97 −1.26 0.114
Pentose Phosphate Pathway 1.97 0.3
Death Receptor Signaling 1.88 −1.26 0.11
Unfolded protein response 1.85 0.132
DNA Methylation and Transcriptional Repression Signaling 1.83 0.2
Mevalonate Pathway I 1.74 0.25
Ephrin Receptor Signaling 1.67 −1.39 0.0872
Agranulocyte Adhesion and Diapedesis 1.61 0.0857
GM-CSF Signaling 1.59 −0.38 0.11
Axonal Guidance Signaling 1.56 0.0703
Gap Junction Signaling 1.52 0.0854
Ketolysis 1.37 0.286
CDK5 Signaling 1.3 −1.34 0.0918
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MDIVI1 inhibits signalling pathways required 
for CSC survival in MCF7 cells
Mitochondrial fusion and fission may also have 
an impact in signalling pathways that regulate stem cell 
proliferation and survival [17]. Thus, we next decided to 
determine how several signalling pathways that regulate 
stemness were affected by mDIVI1 exposure. For that 
purpose, a range of reporter MCF7-GFP cell lines were 
generated, including MCF7-GFP-GLI(luc), MCF7-
GFP-Rbp/Jk(luc), MCF7-GFP-SMAD(luc) and MCF7-
GFP-TCF/LEF(luc), to asses Hedgehog signalling, 
Notch signalling, TGFβ signalling and Wnt signalling 
respectively. These cell lines were exposed to either 
mDIVI1 or vehicle and assessed for luciferase activity. 
For the first time, we show that mDIVI1 treatment 
significantly inhibited all stem-related signalling pathways 
in a dose-dependent manner at most of the time points 
Figure 5: mDIVI1 treatment significantly reduces MCF7 tumorsphere formation, as well as the formation of A375 
melanoma and A549 lung tumorspheres. (A) Five days of treatment with the mitochondrial fission inhibitor mDIVI1 decreased 
tumorsphere number by 50%  at a concentration of 10 µM by 80% at 50 µM and 95% at 100 µM. One-way ANOVA, post test for linear 
trend, ***p value < 0.001. N = 3. (B) Five days of treatment with the mitochondrial fission inhibitor mDIVI1 dose-dependently decreased 
tumorsphere formation efficiency also in a melanoma (A375) and a lung cancer (A549) cell line. Data represented as MEAN ± SEM. One-
way ANOVA, post test for linear trend *p value < 0.05 N = 2. (C) Representative image of A375 melanoma and A549 lung tumorspheres 
after treatment with either vehicle or mDIVI1. Inhibition of DRP1 with mDIVI1 decreased tumorsphere number and also tumorsphere size. 
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evaluated. Particularly, 50 µM mDIVI1 strikingly caused 
the inhibition of the Hedgehog/GLI pathway, the Notch/
Rbp pathway, the Wnt/TCF pathway and the TGFβ/SMAD 
pathway 2 and 5 days after the start of the treatment 
(Figure 7). 
Moreover, STAT3 (-1.83), EphA2 (-1.74) and BMP7 
(-47.17), all proteins involved in signalling pathways 
associated with cancer stem cell activities, were also 
found to be down-regulated in the proteomics datasets. 
Ephrin receptor signalling was specifically found to 
be significantly altered in mDIVI1-treated MCF7 cells 
compared to vehicle, with a negative z score indicating 
a slight inhibition of this pathway (Table 2). Likewise, 
TGFβ was identified by IPA as an upstream regulator 
predicted to be downregulated (z score  =  −1.934). 
In summary, mDIVI1 inhibits all studied signalling 
pathways related with stemness in MCF7 cancer cells, 
confirming a suppression of the stem-like phenotype in 
these cells after treatment. 
MDIVI1 increases CD44+/CD24− population of 
MCF7 cells at high concentrations
In human breast cancers, CSCs were first identified 
by the profile of expression of the cell surface marker 
CD24−/CD44+ [18]. Thus, we next determined the 
expression levels of these CSC markers in MCF7 grown 
either as monolayers or under anchorage-independent 
conditions and exposed to mDIVI1 or vehicle. 
Surprisingly, the abundance of the CD24−/CD44+ 
subpopulation of MCF7 cells was not reduced after 
exposure to 10 or 50 µM mDIVI1 compared to vehicle 
in cells grown as monolayers. Moreover, treatment of 
MCF7 cells in suspension with mDIVI1 unexpectedly 
increased the amount of CD24−/CD44+ cells in a dose-
dependent fashion (Figure 8A and 8B). Thus, mDIVI1 
exposure does not alter the proportion of CD24−/CD44+ 
MCF7 CSCs grown as monolayers. However, under 
anchorage-independent growth conditions, the quantity of 
Figure 6: mDIVI1 treatment significantly reduces MCF7 migration in vitro. (A) Representative image of MCF7 cells after 
treatment with either vehicle or mDIVI1. Inhibition of DRP1 with mDIVI1 reduces scratch closure in vitro. (B) Two days of treatment with 
the mitochondrial fission inhibitor mDIVI1 significantly decreased the percentage of wound closure. Data represented as MEAN ± SEM. 
One-way ANOVA, post test for linear trend ***p value < 0.001. N = 4.
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CD24−/CD44+ MCF7 cells increases in the mDIVI1 
treatments in a dose-dependent manner.
It has been recently described that breast CSCs can 
exist in distinct states, a mesenchymal-like state and an 
epithelial-like state, being the first one characterised for 
its expression of CD24−/CD44+, with a mesenchymal-
like gene-expression profile and primarily quiescent [18]. 
Thus, we hypothesised that the increase in CD24−/CD44+ 
MCF7 cells in suspension after treatment with mDIVI1 
could respond to a change in these cells from an epithelial 
towards a more mesenchymal phenotype. We therefore 
searched for the expression of epithelial markers in MCF7 
cells treated with either vehicle or mDIVI1. Immunoblot 
analysis of MCF7 cells treated with mDIVI1 revealed a 
reduction in the expression of E-cadherin after mDIVI1 
treatment (Figure 8D). Decrease in the expression of other 
epithelial markers was observed also in the proteomics 
datasets, including EPCAM (−1.58), ZO-1 (−1.62), 
keratins 8 and 18 (−5.24 and −12.21), CELSR2, involved 
in loss of polarization (−1.6), F11 receptor (−1.70), 
junction plakoglobin (−1.65) and desmoplakin (−4.58), 
although other epithelial markers such as collagen type 
IV was found to be upregulated by 1.9 fold. However, 
no mesencymal markers were identified as upregulated 
by proteomics. Notably, amongst the altered pathways 
identified by IPA in the mDIVI1-treated cells were 
Table 3: Toxicity effects of differentially expressed proteins and biological functions affected by mDIVI1 treatment 
compared to vehicle-treated MCF7 cells
Categories Biological functions p-Value Activation z-score
Cellular movement
Invasion of cells 0.00000127 −1.806
Invasion of tumour cell lines 0.00000205 −1.652
Cell movement of tumour cell lines 0.0000138 −1.628
Cell movement 0.0000841 −1.295
Migration of tumour cell lines 0.000153 −1.164
Cell movement of breast cancer cell lines 0.000655 −1.968
Cell Cycle, Cellular Movement Cytokinesis 0.0000132 −0.669
Cell Cycle, DNA Replication, 
Recombination, and Repair
Recombination of cells 0.0000153 −1.732
Homologous recombination of cells 0.0000327 −1.732
Homologous recombination 0.000264 −1.387
Cell Cycle Cell cycle progression 0.000218 −1.762
Cell Morphology, Cellular 
Function and Maintenance, DNA 
Replication, Recombination, and 
Repair
Repair of cells 0.00145 1.921
Double-stranded DNA break repair of cells 0.0035 2.069
Cell Morphology
Shape change of tumour cell lines 0.00354 −1.446
Cell spreading 0.00383 −1.633
Cellular Assembly and 
Organization
Formation of cytoskeleton 0.000722 1.95
Formation of nucleus 0.00185 −2
Cellular Function and 
Maintenance Endocytosis 0.000264 −1.832
Cellular Assembly and 
Organization Formation of cytoskeleton 0.000722 1.95
Gene Expression Transcription 0.000829 1.993
DNA Replication, 
Recombination, and Repair Double-stranded DNA break repair 0.000932 2.123
Cell Death and Survival Cell viability 0.00417 −2.813
Ingenuity Toxicity Lists -log (p-value) Ratio
Cholesterol Biosynthesis 3.12 0.312
Fatty Acid Metabolism 3.02 0.133
Decreases Permeability Transition of Mitochondria and Mitochondrial 
Membrane 2.46 0.429
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pathways involved in cell to cell interaction and cell 
junctions such as remodeling of epithelial adherens 
junctions or epithelial adherens junctions signalling, 
tight junction signalling, gap junction signalling or 
FAK, integrin or paxillin signalling (Table 2). Thus, it 
seems mDIVI1 exposure induces the acquisition of a 
CD24−/CD44+ phenotype in MCF7 cells in suspension 
with loss of epithelial markers although no complete 
epithelial-to-mesenchymal transition is observed. 
The DAPI staining that was performed in parallel 
to CD24−/CD44+ staining to be used as quantification of 
viable cells, also revealed that there were no significant 
differences in cell viability between vehicle-treated cells 
and mDIVI1-treated cells under anchorage-independent 
conditions (Figure 8C). That is, mDIVI1-treated cells 
are not propagating as efficiently as vehicle-treated cells 
do, as observed in the tumorsphere formation assay, 
however they are more viable after mDIVI1 treatment 
in suspension than under attachment conditions. One 
possible explanation to that observed behaviour is that 
they are becoming more quiescent. In fact, IPA analysis 
identifies cell cycle, M phase, cytokinesis, cell viability or 
cell proliferation as biological functions that are predicted 
to be decreased in mDIVI1-treated MCF7 cells compared 
to vehicle (Table 3). In addition, treatment with 50 µM 
mDIVI1 showed frequent aberrations associated with 
failure of cytokinesis, which could be seen by DAPI 
immunofluorescence staining as an increase in binucleated 
cells (data not shown). Such phenomenon is typical of 
anti-mitotic drugs.
DISCUSSION
Recent findings show that mitochondrial 
morphology and function contribute to a stem-like 
phenotype, implying that mitochondrial fission and 
fusion are central players in CSC behaviour. The balance 
in mitochondrial dynamics is controlled by a small 
Figure 7: mDIVI1 treatment significantly inhibits stem-related signalling in MCF7 cells. (A) Hh/GLI (B) Notch/Rbp/Jk 
(C) TGFβ/SMAD and (D) Wnt/TCF/LEF signaling were significantly inhibited after treatment with mDIVI1 at most time points assessed, 
particularly after exposure to 50 µM mDIVI1. Data represented as MEAN ± SEM. One sample t test, *p value < 0.05, **p value < 0.01 and 
***p value < 0.001. N = 3
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cohort of regulators, such as DRP1. mDIVI1 is a small 
molecule inhibitor of DRP1 used in research for inhibiting 
mitochondrial fission (Figure 9). Emerging evidence 
demonstrates the implication of mitochondrial fission and 
in particular DRP1 in the tumorigenicity and maintenance 
of stem-like cells [7, 8]. However, a comprehensive 
study of the effects of mDIVI1 on CSC behaviour is still 
needed. Here, we tested the hypothesis that mDIVI1, 
through inhibition of mitochondrial fission, would induce 
loss of oxidative phosphorylation, therefore reducing the 
propagation of CSC, as they rely on their mitochondrial 
metabolism for their survival [11–13]. 
Our results show that mDIVI1-induced inhibition 
of DRP1 in MCF7 cells has a positive effect on their 
mitochondrial mass and production of mitochondrial 
reactive oxygen species, and that has a negative impact 
on mitochondrial metabolism. Mitochondrial fission 
plays a role in mitophagy, as it facilitates the elimination 
of defective organelles via isolation of selective parts 
of the mitochondria from the mitochondrial network. 
Therefore it is not surprising that after inhibiting DRP1, 
a slight increase in mitochondrial mass is observed. 
A few studies associate DRP1 and mitochondrial 
oxidative stress. Mitochondrial ROS levels are lower 
in DRP-overexpressing cells whereas those in a DRP1 
mutant that inhibits mitochondrial fission are increased 
[14]. Moreover, when stress-induced hyperfusion of 
mitochondria happens in differentiated tissue, it increases 
mitochondrial ROS levels [19]. mDIVI1 also causes 
mitochondrial dysfunction and subsequent cell apoptosis 
in a DRP1-dependent manner in chemoresistant breast 
cancer cells [20]. In the current study, we show that 
mDIVI1-induced DRP1 inhibition alters the exctracellular 
acidification rate and oxygen consumption rate of MCF7 
cells, transforming them in less aerobic, less metabolically 
active cells. mDIVI1 treatment seems to also have a big 
impact on lipid metabolism.
Previous studies performed in our lab strongly 
indicate that mitochondrial function has an implication 
in the propagation of CSCs [11–13]. We show here that 
mDIVI1-induced reduction in the respiration of MCF7 
cells also impedes their propagation under anchorage-
independent conditions.  In addition, we show for the 
first time that mDIVI1 treatment decreases tumorsphere 
forming capacity in melanoma and lung cancer cell 
lines. However, the sphere assay has several weaknesses 
as even when plating them at a limiting dilution, 
individual spheres can be formed out of aggregation of 
cells rather than be generated through clonal expansion. 
Furthermore, more differentiated cells can also exhibit 
sphere-forming capability, and because tumorspheres 
themselves are heterogeneous, experiments using them 
should be interpreted as studies of mixed cell populations 
enriched for stem-like cells, not totally purified CSCs [21]. 
Taken together, these considerations made us use other 
approaches to asses CSC phenotype and activity, including 
the evaluation of several stemness-related pathways or the 
migratory ability of mDIVI1-treated MCF7 cells. Indeed, 
via generation of several reporter cell lines, we confirmed 
that mDIVI1 treatment was able to inhibit stemness-
related signalling in MCF7, and mDIVI1 had also a 
negative effect on MCF7 cell motility. 
Increased cell motility and invasion seem to 
require mitochondrial elongation and trafficking to the 
periphery of the cell. Several reports link mitochondrial 
localisation and cell motility by describing a redistribution 
of mitochondria toward the leading edge of cells during 
persistent migration. DRP1 silencing inhibits lamellipodia 
formation, a key step for cancer metastasis, by suppressing 
recruitment of mitochondria to those regions, and therefore 
decreasing the metastatic potential of breast cancer [22]. 
In order to be transported around the cells, mitochondria 
need to be transformed into small units, free from a tight 
network organization. Is during that process that DRP1 
may play a role. Mitochondria might be needed at the 
leading edge as a source of energy, for calcium signalling, 
for the stabilisation of microtubules by ATP or even for the 
production of fatty acids and eicosanoids for membrane 
dynamics in the proximity of focal adhesions [23]. Our 
results show that treatment with mDIVI1 actually alters 
these processes, including oxidative phosphorylation 
and ATP production, lipid metabolism, and calcium 
and focal adhesion signalling (Table 2). Oxidative 
phosphorylation is actually required for the transfer of 
mitochondria to the cortical cytoskeleton. In respiration-
deficient tumour cells, there is a lack of mitochondria 
in focal adhesion complexes, and invasion is impared 
[23]. Thus, via inhibition of mitochondrial fission and 
oxidative phosphorylation, mDIVI1 avoids distribution of 
mitochondria to the leading edge of the cell, and migration 
is impeded. 
Indeed several studies point out that actin 
polymerization promotes mitochondrial fission. In 
addition, actin-depolymerizing drugs inhibit the 
recruitment of DRP1 to mitochondria and mitochondrial 
length is reduced [24]. Our proteomics results also 
show that one of the top canonical pathways affected by 
mDIVI1 is the actin cytoskeleton signalling.
Unexpectedly, we also found an increase in the 
abundance of CD24−/CD44+ cells, which is a marker 
of CSC activity. Breast CSCs can exist in reversible 
heterogeneous states, a more epithelial-like state, and 
a more mesenchymal-like state, characterised for its 
expression of CD24−/CD44+, with marked reduction of 
oxygen consumption and increased quiescence [18]. 
However, although there was a clear reduction of epithelial 
markers after exposure to mDIVI1, as well as a reduction 
of mitochondrial respiration, we could not identify an 
over-expression of mesenchymal markers in mDIVI1-
treated MCF7 cells. Interestingly, during pluripotency 
reprogramming, epithelial-like cells display more 
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Figure 8: mDIVI1 treatment significantly increases the CD24−/CD44+ population of MCF7 cells at high concentrations. 
(A) Representative graph showing CD24/CD44 staining of MCF7 cells treated with either vehicle or mDIVI1 and grown as either 
monolayers or in suspension for 2 or 5 days. (B) CD24−/CD44+ subpopulation of MCF7 cells significantly increased after treatment with 
50 µM of mDIVI1 in suspension. (C) The percentage of anoikis-resistant cells did not significantly differ in mDIVI1 treatments from 
the vehicle treatment. One way ANOVA, Dunnett’s multiple comparisons test, *p value < 0.05, **p value < 0.01 and ***p value < 0.001. 
N = 4 (D) Immunoblot analysis of MCF7 cells treated with mDIVI1 revealed a decrease of E-cadherin expression after mDIVI1 treatments. 
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fragmented mitochondria, indicating that mitochondrial 
fission is critical for the acquisition of pluripotency [9]. 
Finally, compared to vehicle-treated cells, 
mDIVI1-treated cells seem to survive more in suspension 
than under attachment conditions, which could be related 
to the acquisition of a quiescent state. An exhaustive 
analysis of the cell cycle would be strongly advised to 
be able to tell whether these cells are actually acquiring a 
quiescent phenotype or are undergoing senescence. Our 
proteomics datasets did not identify many markers of 
senescence. Only LAMP1 was found to be upregulated 
in mDIVI1-treated cells compared to vehicle (2.83), 
although it is also involved in the processes of autophagy 
and mitophagy.  
In summary, mDIVI1 has a negative impact on the 
anchorage-independent growth of MCF7 cells, on their 
migratory capacity and their signalling pathways related 
to stemness. However, it seems that mDIVI1 selects for 
a phenotype with loss of epithelial markers and features, 
such as cell to cell contact establishment, and in suspension 
enriches the CD24−/CD44+ population of cells. Several 
options could explain that behaviour. The first one could 
be that CD24−/CD44+ expression is not representative 
of CSC activity in this scenario of mitochondrial fission 
inhibition, as for instance DRP1 effects on CSC behaviour 
are downstream of CD44, or mDIVI1 has a direct effect 
in CD24 loss or CD44 acquisition that does not have an 
impact on CSC survival. Another explanation would be 
that MCF7 cells enrich their CD24−/CD44+ expression 
profile to counteract mDIVI1 effects, without being able to 
reverse the inhibition of the CSCs phenotype (tumorsphere 
formation efficiency, migration and stemness signalling) 
and therefore depleting CSCs. 
Metabolism is materialising as a promising area 
for cancer treatment [25]. Nevertheless, the notion of 
targeting cancer mitochondrial metabolism or organelle-
driven adaptation is still underdeveloped. This study 
has been done in an effort to contribute to that concept, 
as a better understanding of processes engaged in 
the regulation of mitochondrial dynamics and their 
significance for CSC maintenance and propagation will 
provide us with the instruments to eventually alter them, 
offering new possible therapeutic approaches. It appears 
that CSCs have adopted metabolic control mechanisms to 
increase their survival and proliferation. In that scenario, 
mitochondrially-targeted drugs may represent promising 
new agents to interfere with tumour adaptation, ultimately 
eliminating CSCs [26]. The fact that mDIVI1 acts as a 
cytoprotective agent in non-tumour cells and that it 
would allow a reversible manipulation of mitochondrial 
morphology highlights its importance as a putative anti-
cancer agent. 
Figure 9: Schematic diagram summarizing our approach using mDIVI1 to investigate the role of mitochondrial fission/
fusion in CSC propagation.  Note that mDIVI1 inhibits DRP1, a mitochondrial-specific dynamin protein.  See text for further details. 
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MATERIALS AND METHODS
Cell culture 
Human MCF7 breast cancer cells were purchased 
from ATCC and maintained in complete media: DMEM 
(D6546, Sigma) supplemented with 10% fetal bovine 
serum (F7524, Sigma), 100 units/ml of penicillin, 100 
µg/ml, streptomycin (P0781, Sigma) and 1% Glutamax 
(#35050087, Life Technologies). For all experiments, cells 
were incubated in a 5% CO2 atmosphere at 37° C. 
Chemicals 
mDIVI1 or 3-(2,4-Dichloro-5-methoxyphenyl) 
2,3-dihydro 2-thioxo-4(1H) quinazolinone (sc-215291, 
Santa Cruz), an inhibitor of mitochondrial division DRP1 
and dynamin I, was used in this study at the concentrations 
indicated. Vehicle-treated cells (DMSO 0.5%) were 
analysed in all experiments.
Prestoblue viability assay
Cell viability was measured using the resazurin-
based PrestoBlue reagent (A-13261, ThermoFisher 
Scientific). Briefly, 5 × 103 MCF7 cells were seeded into 
96-well black plates. When cells were attached mDIVI1 
or vehicle were added to the cells. After 2 or 5 days, 
PrestoBlue reagent was added to the cells and incubated 
for 2 hours. Plates were finally read using a FluoStar 
Omega plate reader (BMG Labtech) at an excitation 
wavelength of 544 and an emission wavelength of 590 
nm. Background measurements were subtracted from all 
values.
Mitochondrial mass quantification
To measure mitochondrial mass, cells were stained 
with MitoTracker Deep Red (M22426, Invitrogen). 
Briefly, 2 × 105 MCF7 cells per well were seeded in 6-well 
plates. When cells were attached, mDIVI1 and vehicle 
treatments were added for 2 days or 5 days in triplicate. 
Cells were then incubated for 15 min at 37° C with the 
10 nM Mitotracker Deep Red probe diluted in PBS 
(D8662, Sigma). All subsequent steps were performed in 
the dark. Cells were washed in PBS, harvested, and re-
suspended in PBS. Mitotracker signal was quantified as 
mean fluorescent intensity of the viable cell population in 
a Fortessa flow cytometer (BD Bioscience). Results were 
analyzed using FlowJo software.
Mitochondrial staining
One hundred thousand MCF7 cells were seeded 
onto coverslips in 12-well plates. When cells were 
attached, mDIVI1 and vehicle treatments were performed 
in triplicate. After 2 days and 5 days, mitochondria were 
labeled by incubating cells for 15 min at 37° C with 25 nM 
of MitoTracker DeepRed (M22426, Invitrogen) diluted in 
PBS (D8662, Sigma). Then, cells were washed with PBS, 
fixed in 2% paraformaldehyde (28908, Thermo Scientific) 
in PBS for 30 minutes at room temperature and mounted 
with ProLong® Gold Antifade Mountant reagent with 
DAPI (P36935, Invitrogen, Inc.). Immunofluorescence 
pictures were taken in a Leica gated Stimulated Emission 
Depletion Microscopy (gSTED) with additional confocal 
and multi-photon illumination (room rg106).
Levels of reactive oxygen species and 
mitochondrial superoxide 
For both assays, 2 × 105 MCF7 cells were seeded in 
35 mm plates. When cells were attached, either vehicle or 
mDIVI1 were added to the cells for 24, 48 hours or 5 days 
in triplicate. Reactive oxygen species (ROS) production 
was measured using CM-H2DCFDA (C6827, Invitrogen). 
Briefly, cells were incubated for 20 minutes at 37° C with 
1 µM CM-H2DCFDA diluted in PBS and then placed in 
complete media for 20 minutes at 37° C in the dark, to 
render the dye fluorescent, according to the manufacturer. 
Mitochondrial superoxide was measured using MitoSOX 
Red Mitochondrial Superoxide Indicator (M36008, 
ThermoFisher Scientific).  Briefly, cells were incubated 
for 10 minutes at 37° C in the dark with 5 µM MitoSOX 
diluted in PBS, according to the manufacturer. ROS signal 
and MitoSOX signal was quantified as mean fluorescent 
intensity of the viable cell population in a Fortessa flow 
cytometer (BD Bioscience). Results were analysed using 
FlowJo software.
Extracellular flux analysis and bradford assay
Extracellular acidification rate (ECAR) and oxygen 
consumption rate (OCR) were measured in a XF96 
Extracellular Flux Analyzer (Seahorse Biosciences). 
Briefly, 1 × 104 MCF7 cells per well were seeded in 
XF96 plates and incubated with complete medium. When 
cells were attached, mDIVI1 and vehicle treatments 
were added. Six replicates were run for each condition. 
After 48 hours, un-buffered DMEM XF medium 
supplemented with 2 mM glutamine (pH 7.4) was added 
to the cells, and placed in a 37° C CO2-free incubator 
for 1 hour. Ten mM glucose, 1 μM oligomycin and 
100 mM 2-deoxyglucose (2-DG) were injected into the 
media at different time points and ECAR was measured. 
Likewise, ECAR and OCR were quantified using un-
buffered DMEM XF medium supplemented with 2 mM 
glutamine, 2 mM sodium pyruvate and 10 mM glucose. 
One μM oligomycin, 0.9 μM FCCP and 1 μM rotenone 
and antimycin A were injected into the media at different 
time points and OCR and ECAR were measured. 
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Cells were finally lysed with 0.1 M NaOH and 
protein lysate was subsequently stained with Quick 
Start™ Bradford 1× Dye Reagent (500–0205, BioRad) 
to normalise results. All parameters were calculated 
according to manufacturer.
Tumorsphere formation assay
A single cell suspension was prepared using 
enzymatic (1× Trypsin-EDTA, T3924, Sigma Aldrich), 
and manual disaggregation (25 gauge needle) [27]. Cells 
were plated at a density of 5000 cells/well in tumorsphere 
media (DMEM-F12/B27/EGF (20ng/ml)/Pen-Strep) in 
non-adherent conditions, in 6-well plates coated with 
(2-hydroxyethylmethacrylate) (poly-HEMA, P3932, 
Sigma) in the presence of mDIVI1 or vehicle. After 5 days 
of culture in a humidified incubator at 37° C, tumorspheres 
bigger than 50 μm were counted using an eye piece 
graticule.
Scratch assay
A hundred thousand MCF7 cells per well were 
seeded in 12-well plates. When cells were attached, a 
horizontal scratch was performed using the tip of a pipette. 
Immediately after, the media was removed and either fresh 
vehicle-containing media or mDIVI1-containing media 
were added to the cells for 48 hours. Four replicates were 
used for each condition. Cells were incubated in a 5% 
CO2 atmosphere at 37° C in an Incucyte ZOOM System 
(Essen Bioscience). The wound closure was monitored 
by taking pictures of each well every 4 hours. At the end 
of the treatment, pictures of the wells at 0 and 48 hours 
were analysed using ImageJ software to calculate wound 
closure according to the following formula:
Percentage wound closure = [(wound area0h – wound 
area48h) / wound area0h] x 100
Luciferase assay
The Cignal Lenti reporter assay (luc) was used to 
monitor the activity of several signalling pathways in 
MCF7-GFP cells as explained previously [28]. Luciferase 
Assay System (E1501, Promega) was performed according 
to manufacturer’s instructions. 1 × 104 MCF7 were 
seeded in black-walled 96 well plates. When cells were 
attached, drug treatments were added for 18, 48 hours and 
5 days. After treatment, Luciferase Assay was performed 
according to manufacturer’s instructions and light signal 
was acquired in the Xenogen VivoVision IVIS Lumina. 
Results were normalized by SRB staining of cells grown 
in 96-well plates in parallel.  
Sulforhodamine b (SRB) assay
SRB (S9012, Sigma) measures total biomass by 
staining cellular proteins. After treatment, cells were 
fixed in 10% tricloroacetic acid (T9159, Sigma) for 
1 hour at 4° C, stained with SRB (S9012, Sigma) for 15 
minutes, and washed 3 times with 1% acetic acid (27225, 
Sigma). The incorporated die was solubilized with 10 
mM Tris Base, pH 8.8 (T1503, Sigma). Absorbance was 
spectrophotometrically measured at 562 nm in a FluoStar 
Omega plate reader (BMG Labtech). Background 
measurements were subtracted from all values.
CD24/CD44 expression 
Four hundred thousand MCF7 cells were seeded 
either in either a regular 10 cm dish or in five 15 cm dishes 
coated with (2-hydroxyethylmethacrylate) (poly-HEMA, 
P3932, Sigma) in the presence of mDIVI1 or vehicle for 
2 days or 5 days. Following mDIVI1 treatment, MCF7 
cells grown either in suspension or as monolayers were 
analysed for their expression of CD24 and CD44. The 
surviving fraction after 2 days and 5 days of growth was 
analyzed by FACS. MCF7 cells were either trypsinised 
or spun down and trypsinised and incubated with CD24 
(IOTest CD24-PE, Beckman Coulter) and CD44 (APC 
mouse anti-human CD44, 559942, BD Pharmingen) for 15 
minutes on ice. Cells were then rinsed twice in PBS, spun 
down, and resuspended with DAPI dye (D1306, Molecular 
probes) at 3 µM in PBS for 10 minutes. Samples were then 
analyzed by FACS (Fortessa, BD Bioscence). Only the live 
cell population, identified using the DAPI staining, was 
analyzed for CD24/CD44 expression. Data were analyzed 
using FlowJo software. Only those cells expressing CD44 
that did not express CD24 were considered to be the 
CD24−/CD44+ CSC subpopulation. 
Western blotting 
Two million MCF7 cells were seeded either in 
regular 15 cm dishes or in five 15 cm dishes coated 
with (2-hydroxyethylmethacrylate) (poly-HEMA, 
P3932, Sigma) in the presence of mDIVI1 or vehicle 
for 2 days or 5 days. At the end of the treatment, cells 
in suspension were spun down and lysed and attached 
cells were directly lysed in RIPA lysis buffer (R0278, 
Sigma) containing proteinase inhibitors (05 892 970 
001, Roche) and kept at 4° C for 20 minutes with 
rotation. Lysates were cleared by centrifugation for 10 
minutes at 10,000 xg and supernatants were collected. 
Equal amounts of protein lysate, as determined by 
using the BCA protein assay kit (23225, Pierce) were 
diluted in SDS sample buffer and dry-boiled for 5 
minutes before being separated by SDS-PAGE using 
4–20% gels (456–1094, Biorad). Samples were then 
blotted onto nitrocellulose membranes (170–4159, 
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Biorad), blocked in 5% milk in TBS-Tween 20 (P9416, 
Sigma) for 1 hour and probed with antibodies against 
E-cadherin (ab8995, Abcam) or β-actin (a2228, Sigma). 
Bound antibodies were detected using a horseradish 
peroxidase-conjugated secondary antibody (ab6789 
and ab6721, Abcam) and signal was obtained using 
Supersignal West Pico chemiluminiscent substrate 
(34087, ThermoScientific). Pictures were taken in a 
ChemiDoc XRS with Image Lab Software (BioRad).
Label-free semi-quantitative proteomics
Chemicals and sample preparation.
Formic acid, trifluoroacetic acid, ammonium 
formate (10 M), ammonium bicarbonate TCEP (Tris 
(2-carboxyethyl)phosphine hydrochloride), MMTS 
(Methyl methanethiosulfonate)  and trypsin were all 
obtained from Sigma. HPLC gradient grade acetonitrile 
was obtained from Fisher Scientific. Briefly, 2 × 106 
MCF7 cells were seeded in 15 cm plates until cells were 
attached. Cells were then treated with 10 µM mDIVI1. As 
control, vehicle-treated cells were processed in parallel. 
After 48 hours of treatment, cells were lysed in RIPA 
buffer (R0278, Sigma) and kept at 4° C for 20 minutes 
with rotation. Lysates were cleared by centrifugation for 
10 minutes at 10,000 × g and supernatants were collected 
and kept frozen at −80° C.
Protein digestion
Lysate samples were thawed to room temperature 
and their concentrations equalised to 1 µg/µL (50 µL 
volume) with RIPA buffer, and further processed for 
trypsin digestion by sequential reduction of disulphide 
bonds with TCEP and alkylation with MMTS. Briefly, 
1 µL benzonase (Novagen) was added to the 50 µL aliquot 
and placed on ice for 15 minutes. The sample was then 
taken to dryness using a SpeedVac, and resuspended in 
22.5 µL trypsin reaction buffer (40 mM ammonium 
bicarbonate and 9% acetonitrile). One µL of 50 mM 
TCEP solution was added to each sample, mixed briefly 
and placed on a heater block at 60° C for 60 minutes. 
After cooling to room temperature, 0.5 µL of 200 mM 
MMTS solution was added to each sample and allowed to 
react for 15 minutes. Trypsin was added in two waves to 
ensure efficient digestion of the sample. Firstly, 20 µg of 
sequencing grade trypsin was resuspended in 1800 µL of 
trypsin reaction buffer; 225 µL of this solution were added 
to each sample for digestion, and the reactions were left 
at 37° C overnight with shaking (600 rpm). The following 
morning, a further aliquot of trypsin was added. Two ml of 
trypsin reaction buffer was added to 20 µL of sequencing 
grade trypsin; 250 µL of this solution were added to each 
of the digest samples from overnight, and the reactions 
were left at 37° C for 4 hours with shaking (600 rpm). 
Thirty-five µL 10% formic acid were added to the 500 µL 
digest sample (0.7% final concentration of formic acid) to 
stop the digestion. The digested solution was diluted in 7.5 
mL of acetonitrile containing 0.3% formic acid.
HILIC solid phase extraction (SPE) of peptides
PolyhydroxyethylA SPE 12 µm, 300A, 300mg 
cartridges (obtained from PolyLC) were used for the 
HILIC procedure. Prior to use, cartridges required 
an overnight soak in 50 mM formic acid followed by 
rinsing with water the following day. Cartridges were 
preconditioned with 2 mL of Buffer A (90% acetonitrile, 
5 mM ammonium formate, pH 2.7) followed by 2 mL of 
Buffer B (5mM ammonium formate, pH 2.7) and finally 
re-equilibrated with 10 mL Buffer A. The diluted samples 
were loaded onto the cartridges and washed with a further 
10 mL Buffer A. Finally, peptides were eluted in 1 mL 
Buffer C (9 parts Buffer B plus 1 part Buffer A) and the 
samples dried on a Speedvac to remove organic solvent 
prior to LC-MS/MS analysis.
LC-MS/MS analysis
Lyophilised digests were resuspended in 50 µL 
of 0.1% TFA to give an approximate concentration 
of 1 µg/µL. One µL injection volumes were used 
throughout resulting in an on-column peptide loading of 
approximately 1 µg per injection. Analysis was performed 
in quintuplicate for each sample. All LC-MS/MS 
analyses were performed on an LTQ Orbitrap XL mass 
spectrometer coupled to an Ultimate 3000 RSLCnano 
system (Thermo Scientific). One µL injection volumes 
were used throughout and samples loaded directly onto 
the analytical column, PepMap RSLC C18, 2 µm × 75 
µm id × 50 cm (Thermo Scientific). The composition (v/v) 
of LC buffers were as follows; Buffer A - 99.9% water 
plus 0.1% formic acid and Buffer B  −80% acetonitrile, 
19.9% water and 0.1% formic acid. Peptides were loaded 
directly onto the column at a flow rate of 400 nl/min with 
an initial mobile phase composition of 1% B. The organic 
strength was increased linearly from 1% to 22.5% B over 
22.5 minutes again at 400 nl/min, followed by an increase 
to 24.8% B over the next 2.6 minutes with a concomitant 
reduction in flow rate to 300 nl/min, and to 39% B over a 
further 14 minutes. A further increase to 60% B over the 
next 5 minutes was followed by a ramp to 95% B over 
2.5 minutes where it was held for a further 2 minutes. The 
column was then allowed to re-equilibrate to 1% B for a 
total analysis time of 74 minutes. The mass spectrometer 
was instructed to perform data dependent acquisition on 
the top six precursor ions, which were measured in the 
Orbitrap FTMS detector over the mass range 370–1200 
m/z, at a nominal resolution of 60,000. MS/MS spectra 
were acquired in the ion trap under CID conditions with 
normalized collision energy of 35, isolation width of 3 
Th, Q value of 0.25 and 30 ms activation time. Gas-phase 
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fractionation was performed on the five replicate injections 
such that MS/MS data was collected for precursor ion 
range 370–494 m/z Injection 1, 494–595 m/z Injection 
2, 595–685 m/z Injection 3, 685–817 m/z Injection 4 and 
817–1200 m/z Injection 5.
Analysis
Xcalibur raw data files acquired on the LTQ-
Orbitrap XL were directly imported into Progenesis LCMS 
software (Waters Corp) for peak detection and alignment. 
Data were analysed using the Mascot search engine. Five 
replicates were analysed for each sample type (N = 5). 
Ingenuity pathway analyses
Pathway and function analyses were generated 
using Ingenuity Pathway Analysis (IPA) (Ingenuity 
systems, http://www.ingenuity.com), which assists with 
proteomics data interpretation via grouping differentially 
expressed genes or proteins into known functions and 
pathways. Pathways with a z score > 1.9 were considered 
as significantly activated, and pathways with a z score 
< −1.9 were considered as significantly inhibited.
Statistical analyses
ANOVA was used for statistical comparison of three 
or more groups. For normalised data, one-sample t test 
was performed. All data are reported as mean ± standard 
deviation of the mean (SEM). All experiments were 
performed at least three times with reproducible results 
unless otherwise stated. P values lower than 0.05 were 
considered significant (*P < 0.05, **P < 0.01, ***P < 0.001). 
Microsoft Excel was used to produce all graphs except 
FACS analysis graphs, in which case FlowJo was used.
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